KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) EBIT Margin (2016 - 2025)

Jazz Pharmaceuticals has reported EBIT Margin over the past 16 years, most recently at 21.25% for Q4 2025.

  • Quarterly EBIT Margin rose 372.0% to 21.25% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 5.45% through Dec 2025, down 2306.0% year-over-year, with the annual reading at 10.08% for FY2025, 2769.0% down from the prior year.
  • EBIT Margin was 21.25% for Q4 2025 at Jazz Pharmaceuticals, up from 5.11% in the prior quarter.
  • Over five years, EBIT Margin peaked at 26.68% in Q1 2021 and troughed at 65.64% in Q2 2025.
  • The 5-year median for EBIT Margin is 10.76% (2022), against an average of 5.89%.
  • Biggest five-year swings in EBIT Margin: surged 6215bps in 2021 and later crashed -8512bps in 2025.
  • Tracing JAZZ's EBIT Margin over 5 years: stood at 5.51% in 2021, then crashed by -592bps to 27.09% in 2022, then surged by 145bps to 12.11% in 2023, then surged by 45bps to 17.53% in 2024, then increased by 21bps to 21.25% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 21.25%, 5.11%, and 65.64% for Q4 2025, Q3 2025, and Q2 2025 respectively.